Depot Buprenorphine Injection in the Management of Opioid Use Disorder: From Development to Implementation [Corrigendum]

Ling W, Shoptaw S, Goodman-Meza D. *Subst Abuse Rehabil.* 2019;10:69–78.

The authors of this paper have advised that [Table 1](#) is incorrect. The authors advised that they had listed values for C_{max} and C_{trough} after a single dose of Brixadi

(CAM2038) and not steady state, as it was provided for Sublocade. The new [Table 1](#) reflects the Brixadi steady state concentrations for a more direct comparison with Sublocade.

The correct [Table 1](#) is as follows:

Table 1 Comparison of Long-Acting Formulations of Buprenorphine FDA-Approved for Treatment of Opioid Use Disorder

Brand Name	Probuphine	Sublocade	Brixadi (US) or Buvidal (Europe/Australia)
Molecular name		RBP-6000	CAM2038
Pharmaceutical	Previously Braeburn, currently Titan	Indivior	Braeburn Pharmaceuticals/Camurus
Indicated population	Stable transmucosal buprenorphine dose of 8 mg or less for three months or longer	Initiated transmucosal buprenorphine (8–24 mg) for a minimum of 7 days.	Initiation of treatment in patients not already receiving buprenorphine or switching from transmucosal buprenorphine
Route of administration	Subcutaneous implant	Subcutaneous injection	Subcutaneous injection
Duration of effect	6 months	1 month	1 week or 1 month
Dosage	320 mg (Four 80 mg implants)	100 and 300 mg	8, 16, 24 and 32 mg (weekly) or 64, 96 and 128 mg (monthly)
Long acting technology	Ethylene vinyl acetate (EVA) polymer	18% (weight/weight) buprenorphine base in the ATRIGEL Delivery System	Prolonged release FluidCrystal injection depot technology
Location	Upper arm	Abdomen	Buttock, thigh, stomach (abdomen) or upper arm
FDA-approval	2016	2017	2018 (tentative)
Plasma concentrations (ng/mL)	C _{max} 3.23 C _{trough} 0.72	C _{max} 4.88 (100 mg) 10.12 (300 mg) C _{trough} 2.48 (100 mg) 5.01 (300 mg)	C _{max} Weekly 4.3–6.9 Monthly 4.0–11.1 C _{trough} Weekly 0.8–2.6 Monthly 1.3–2.1

(Continued)

Table I (Continued).

Brand Name	Probuphine	Sublocade	Brixadi (US) or Buvidal (Europe/Australia)
Provider burden	+++ Live training program Procedural competency	++ Supervised injection Monthly injections	++ Supervised injection Weekly or monthly injections
Special Handling Requirements	Requires implant procedure Need for removal or replacement every 6 months	Needs Refrigeration Injection only under skin around umbilicus	No special requirements

Substance Abuse and Rehabilitation

Dovepress

Publish your work in this journal

Substance Abuse and Rehabilitation is an international, peer-reviewed, open access journal publishing original research, case reports, editorials, reviews and commentaries on all areas of addiction and substance abuse and options for treatment and rehabilitation. The

manuscript management system is completely online and includes a very quick and fair peer-review system. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/substance-abuse-and-rehabilitation-journal>